Skip to main content
Ultragenyx Pharmaceutical Inc. (RARE)
NASDAQ: RARE · Real-Time Price · USD
24.53
+0.54 (2.25%)
Apr 28, 2026, 4:00 PM EDT - Market closed

Ultragenyx Pharmaceutical Revenue by Segment
Period Ending Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022Mar 31, 2022Dec 31, 2021Sep 30, 2021Jun 30, 2021Mar 31, 2021Dec 31, 2020Sep 30, 2020
Product
369.31M 339.18M 321.49M 314.47M 285.47M 265.30M 230.30M 198.70M
Product Growth
29.37% 27.85% 39.59% 58.26% 58.24% 68.34% 55.82% 45.67%
Other
303.42M 291.43M 288.69M 276.21M 274.71M 257.40M 250.90M 243.80M
Other Growth
10.45% 13.22% 15.06% 13.29% 8.24% 1.90% 2.37% 2.65%

Revenue by Geography
Period Ending Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022Mar 31, 2022Dec 31, 2021Sep 30, 2021Jun 30, 2021Mar 31, 2021Dec 31, 2020Sep 30, 2020
North America
361.22M 354.58M 340.56M 340.46M 316.40M 307.30M 297.70M 307.10M
North America Growth
14.16% 15.39% 14.40% 10.86% 5.82% 3.05% 4.02% 9.29%
Latin America
149.83M 144.47M 150.40M 130.71M 130.30M 109.50M 89.70M 77.30M
Latin America Growth
14.99% 31.93% 67.67% 69.10% 93.32% 70.30% 55.46% 72.93%
Europe
103.33M 97.65M 87.45M 80.12M 69.60M 60.40M 54.20M 47.60M
Europe Growth
48.47% 61.68% 61.35% 68.33% 63.00% 58.53% 44.15% 30.77%
Japan
12.64M 9.79M 8.69M - 6.40M 4.10M - 2.20M
Japan Growth
97.48% 138.66% - - - - - -
Source: Business metrics provided by Main Street Data and sourced from official company press releases and documents.